Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review (Q26750470)

2

0 references

Alberto Torres

3

0 references

Luis de la Cruz

4

0 references

Tomas Martín

Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients

5

0 references

language of work or name

English

0 references

publication date

February 2016

0 references

published in

Endocrine-Related Cancer

0 references

volume

23

0 references

issue

2

0 references

page(s)

R71-84

0 references

cites work

1 reference

7 January 2021

Reporting results of cancer treatment

1 reference

7 January 2021

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

1 reference

7 January 2021

Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study

1 reference

7 January 2021

Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer

1 reference

7 January 2021

A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer.

1 reference

7 January 2021

GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.

1 reference

7 January 2021

Cytotoxic chemotherapy for differentiated thyroid carcinoma.

1 reference

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

7 January 2021

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

1 reference

7 January 2021

Chemotherapy for thyroid cancer

1 reference

7 January 2021

Treatment of metastatic thyroid cancer

1 reference

7 January 2021

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

7 January 2021

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

1 reference

7 January 2021

Combined doxorubicin and bleomycin treatment of metastasising thyroid carcinoma: results in 21 patients (author's transl)

1 reference

7 January 2021

Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium

1 reference

7 January 2021

Results of chemotherapy in thyroid cancer

1 reference

7 January 2021

Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.

1 reference

7 January 2021

Motesanib diphosphate in progressive differentiated thyroid cancer.

1 reference

7 January 2021

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

1 reference

7 January 2021

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

1 reference

7 January 2021

Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

1 reference

7 January 2021

Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy

1 reference

7 January 2021

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

1 reference

7 January 2021

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

1 reference

7 January 2021

Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer

1 reference

7 January 2021

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

1 reference

7 January 2021

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

1 reference

7 January 2021

Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors

1 reference

7 January 2021

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.

1 reference

7 January 2021

Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma refractory to I131 treatment

1 reference

7 January 2021